• Carfilzomib (PR-171): Mechanism-Informed Strategies in Oncol

  2026-05-04

  This thought-leadership article provides translational oncology researchers with mechanistic insight and strategic guidance for deploying Carfilzomib (PR-171) in cancer research. By bridging proteasome biology, emerging combination therapies, and practical assay optimization, the article delivers evidence-based recommendations and positions APExBIO’s Carfilzomib as an essential tool for reproducible, high-impact studies.

• Applied Cancer Research with Pazopanib Hydrochloride (GW7860

  2026-05-04

  Pazopanib Hydrochloride (GW786034) stands out as a multi-target tyrosine kinase inhibitor, enabling rigorous, reproducible anti-angiogenic and tumor growth assays in cancer research. This article translates advanced in vitro metrics and troubleshooting insights into actionable protocols, maximizing the translational impact of this agent for renal cell carcinoma and soft tissue sarcoma models.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-05-03

  The referenced study uncovers how certain kinase inhibitors not only suppress p38α MAPK activity but also promote its dephosphorylation by stabilizing an activation loop conformation preferred by phosphatases. This dual-action mechanism provides new insights into achieving enhanced specificity and potency in kinase-targeted research and therapeutic strategies.

• Improving In Vitro Evaluation of Cancer Drug Responses: Insi

  2026-05-02

  Schwartz et al. present a nuanced analysis of drug response metrics in cancer research, distinguishing between proliferative arrest and cell killing in vitro. Their findings highlight the importance of measuring both relative and fractional viability to more accurately assess anti-cancer drug effects, informing better preclinical evaluation and experimental design.

• Cabozantinib (XL184): Translational Roadmap for RCC Adaptati

  2026-05-01

  Explore the mechanistic complexity and translational implications of Cabozantinib (XL184) in renal cell carcinoma (RCC) research. This article leverages recent phosphoproteomic evidence to guide experimental design, highlight strategic considerations in kinase inhibitor adaptation, and position APExBIO’s high-purity Cabozantinib as a critical tool for next-generation cancer biology workflows.

• Reliable Immune Assays with Tofacitinib Citrate (CP-690550 c

  2026-05-01

  This article provides a scenario-driven, evidence-based guide for laboratory scientists leveraging Tofacitinib citrate (CP-690550 citrate), SKU A4135, in immune regulation and inflammatory disorder research. Through real-world experimental questions and quantitative results, it demonstrates how this selective JAK3 inhibitor from APExBIO ensures reproducibility, sensitivity, and workflow safety across cell viability and proliferation assays.

• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding

  2026-04-30

  Oliveira et al. (2025) demonstrate that naturally occurring angiotensin peptides, including short C- and N-terminal fragments, significantly enhance the binding of SARS-CoV-2 spike protein to the AXL receptor. These findings provide new mechanistic insights into the intersection of the renin-angiotensin system and viral pathogenesis, with implications for hypertension and COVID-19 research.

• DNA Damage Biomarkers Enhance Specificity of In Vitro Micron

  2026-04-30

  This study demonstrates that integrating DNA damage response biomarkers with flow cytometry-based micronucleus (MN) assays in TK6 cells improves the specificity of genotoxicity detection without compromising sensitivity. The approach offers a clearer distinction between true genotoxicants and false positives, informing more reliable chemical safety assessments.

• Retinoic Acid Overcomes Cisplatin-Induced PARP Inhibitor Res

  2026-04-29

  This study demonstrates that all-trans retinoic acid (ATRA) can resensitize epithelial ovarian cancer (EOC) cells to PARP inhibition after resistance is induced by cisplatin. The findings highlight a promising combination approach to address PARP inhibitor resistance, a major challenge in EOC treatment, and provide mechanistic insight relevant to maintenance therapy strategies.

• Novobiocin Sodium: New Horizons in Anti-Parasitic and DNA Da

  2026-04-29

  Explore how Novobiocin Sodium, a leading aminocoumarin antibiotic, is redefining anti-parasitic and DNA damage studies. This article provides an in-depth, evidence-based perspective beyond bacterial assays, highlighting novel research applications and practical assay guidance.

• Atorvastatin in Ferroptosis and Vascular Biology: Mechanisti

  2026-04-28

  Explore how Atorvastatin, a leading HMG-CoA reductase inhibitor, advances both cholesterol metabolism research and ferroptosis-driven cancer therapy. This article uniquely connects molecular mechanisms with assay design to inform next-generation cardiovascular and oncology studies.

• Indazole/Indole Glucagon Receptor Antagonists: New SAR and S

  2026-04-28

  This study reports the discovery and structure–activity relationships (SAR) of a novel series of indazole- and indole-based glucagon receptor antagonists. The research provides new synthetic routes and demonstrates potent in vitro and in vivo efficacy, with implications for type 2 diabetes therapy and advanced amide bond formation strategies.

• AG-490 (Tyrphostin B42): JAK2/EGFR Inhibition in Cancer Mode

  2026-04-27

  AG-490 (Tyrphostin B42) is a potent JAK2 and EGFR inhibitor used for dissecting signal transduction pathways in cancer and immunopathology. Its activity profile enables robust suppression of JAK-STAT and MAPK signaling. This article details its mechanisms, benchmarks, and practical application limits.

• Urolithin A: Advancing Mitochondrial Quality in Fibrosis Res

  2026-04-27

  This thought-leadership article explores how Urolithin A (3,8-dihydroxy-6H-benzo[c]chromen-6-one) transforms mitochondrial biogenesis research, with a particular focus on its mechanistic synergy with glutamine metabolism and translational applications in liver fibrosis. Integrating the latest findings on hepatic stellate cell metabolism and mitochondrial quality control, the article provides strategic guidance, protocol parameters, and a forward-looking perspective for translational researchers.

• Afatinib (BIBW 2992): Precision Inhibition in Assembloid Mod

  2026-04-26

  Afatinib (BIBW 2992) empowers researchers to dissect drug resistance and optimize targeted therapy in physiologically relevant gastric cancer assembloid systems. This guide translates the latest assembloid modeling advances into practical, stepwise workflows—covering protocol specifics, troubleshooting, and the unique advantages of APExBIO’s high-purity Afatinib for robust, reproducible results.

16579 records 1/1106 page Next 12345 下5页 Last page